New York, U.S. | Xinhua | U.S. pharmaceutical company Pfizer Inc. on Tuesday presented weaker-than-expected operating guidance for 2022 leading to material loss of its stock price. Pfizer expects to realize 98 billion to 102 billion U.S. dollars of revenues in 2022 and the mid-point of the guidance range represents a …
Read More »